Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.


e15115 Background: A Phase III clinical trial ( NCT00321620 ) recently demonstrated that denosumab delayed time to 1st skeletal-related event (SRE) and subsequent SREs longer than zoledronic acid (ZA), but showed no difference in either survival or disease progression between the two products. The objective of this study was to conduct an economic… (More)